ADR Therapeutics Commences Joint Research with Medical Arc on Canine Joint and Inflammatory Diseases Using 'Neocella'
ADR Therapeutics, a subsidiary of ADR120S, has commenced research on the application of its next-generation extracellular particle product 'Neocella' for canine joint and inflammatory diseases, based on an existing research agreement with Medical Arc.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 19:30
- 🔍 Collected: May 22, 2026 at 11:01
- 🤖 AI Analyzed: May 22, 2026 at 12:56 (1h 54m after Collected)
ADR Therapeutics, a subsidiary of ADR120S (TSE Standard: 3750, President: Michimichi Hashimoto), has commenced research on the application of its next-generation extracellular particle product 'Neocella' for companion animals (dogs), based on a joint research agreement concluded with Medical Arc (President: Hiroshi Ito), effective May 21, 2026.
Background: Increasing Demand for Regenerative Medicine in Companion Animals
In recent years, the aging trend in companion animals has accelerated, leading to a rapidly increasing demand for 'regenerative medicine' to address chronic inflammation, joint diseases, and gait disorders. Domestically and internationally, various research initiatives are underway to address these challenges.
Overview and Purpose of the Joint Research
This joint research project will be spearheaded by Dr. Hiroshi Ito, President of Medical Arc and Professor Emeritus at Tokyo University of Agriculture and Technology. The study will explore the potential of 'Neocella' in ameliorating conditions and suppressing inflammation in dogs suffering from inflammatory diseases, joint diseases, and other age-related pathologies. Researchers will use 'Neocella' in actual clinical treatments, accumulate case records and post-treatment follow-up data, and conduct veterinary analysis and evaluation.
Key Considerations of the Joint Research:
- Observational research on inflammatory conditions in the small animal (dog) field
- Examination of potential applications for joint diseases and gait disorders
- Evaluation of the utility of cell-derived components in the small animal field
- Accumulation of case data and veterinary analysis
- Collection of foundational data for the overseas licensing of Neocella
Multifaceted Approach Toward Early Commercialization
ADR Therapeutics is pursuing joint research through multifaceted approaches, not limited to this project, aiming for the early commercialization of 'Neocella.'
With the commencement of this research targeting companion animals (dogs), the company aims to further expand the potential applications of 'Neocella' to the small animal field and create new veterinary value.
Future Outlook
The impact of the commencement of this joint research on the company's financial results is considered minor at this stage. The company will promptly announce any matters that need to be disclosed in the future.
Background: Increasing Demand for Regenerative Medicine in Companion Animals
In recent years, the aging trend in companion animals has accelerated, leading to a rapidly increasing demand for 'regenerative medicine' to address chronic inflammation, joint diseases, and gait disorders. Domestically and internationally, various research initiatives are underway to address these challenges.
Overview and Purpose of the Joint Research
This joint research project will be spearheaded by Dr. Hiroshi Ito, President of Medical Arc and Professor Emeritus at Tokyo University of Agriculture and Technology. The study will explore the potential of 'Neocella' in ameliorating conditions and suppressing inflammation in dogs suffering from inflammatory diseases, joint diseases, and other age-related pathologies. Researchers will use 'Neocella' in actual clinical treatments, accumulate case records and post-treatment follow-up data, and conduct veterinary analysis and evaluation.
Key Considerations of the Joint Research:
- Observational research on inflammatory conditions in the small animal (dog) field
- Examination of potential applications for joint diseases and gait disorders
- Evaluation of the utility of cell-derived components in the small animal field
- Accumulation of case data and veterinary analysis
- Collection of foundational data for the overseas licensing of Neocella
Multifaceted Approach Toward Early Commercialization
ADR Therapeutics is pursuing joint research through multifaceted approaches, not limited to this project, aiming for the early commercialization of 'Neocella.'
With the commencement of this research targeting companion animals (dogs), the company aims to further expand the potential applications of 'Neocella' to the small animal field and create new veterinary value.
Future Outlook
The impact of the commencement of this joint research on the company's financial results is considered minor at this stage. The company will promptly announce any matters that need to be disclosed in the future.
FAQ
ADRセラピューティクスとメディカル・アークの共同研究の内容は？
愛玩動物（イヌ）を対象とした次世代細胞外粒子「Neocella」の応用研究です。炎症性疾患や関節疾患、加齢性病態に対する病態改善および炎症抑制の可能性を検討します。
共同研究はいつから開始されましたか？
2026年5月21日から開始されました。
本研究の目的は何ですか？
症例実績や治療後の経過観察データの蓄積、獣医学的な解析・評価を行い、将来的な海外ライセンス導出に向けた基礎データの収集を目指します。
メディカル・アークの役割は何ですか？
同社代表取締役の伊藤博氏（東京農工大学名誉教授）が中心となり、研究プロジェクトを推進します。
「Neocella」とは何ですか？
ADRセラピューティクスが開発を進める次世代細胞外粒子です。